Review Article

Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms

Table 1

In vitro antibacterial effect of ebselen on Gram-positive bacteria and mycobacteria.

MicroorganismStrainMIC (μg/mL)Reference

E. faeciumClinical {27}2[58]

S. aureusClinical {5}0.25–1[54]

Enterococcus spp.VRE64[46]
S. aureusMRSA64
MSSA0.5

S. aureusClinical2.2[55]

Bacillus spp.B. cereusATCC 145790.9[56]
B. subtilisATCC 66330.14
S. aureusATCC 292131.1
M. tuberculosisH37 Rv10

M. tuberculosisH37 Rv20[15]

S. aureusUSA 300/4000.25[57]

E. faecalisClinical {39}0.78[43]
Staphylococcus spp.S. aureusMRSA {60}1.56
CNSClinical {33}0.78

Staphylococcus spp.S. aureusATCC 2592334[32]
S. simulans103P55

Staphylococcus spp.S. aureusMRSA {11}0.125–0.5[16]
Linezolid-resistant S. aureus (NRS 119)0.125
Mupirocin-resistant S. aureus (NRS 107)0.125
VRSA {11}0.125–0.5
MSSA (ATCC 6538)0.125
S. epidermidisNRS 1010.5

Enterococcus spp.E. faecalisATCC (49533, 7080, 49532, 14506, and 51229) (VRE)0.25–1.0[52]
SF 24397/244130.125
SF280730.625
HH22/MMH 594/SV587 (VRE)0.125
E. faeciumE11620.25
E0120 (VRE)/ERV102 (VRE)0.5
ATCC 6569 and ATCC 700221 (VRE)0.5–1
Staphylococcus spp.S. aureusMRSA {6}0.125–0.25
MSSA {2}0.25
VISA {2}0.125–0.25
VRSA {4}0.125–0.25
Streptococcus spp.S. pyogenesATCC 12340.5
S. agalactiaeMNZ (938, 933, and 929)0.5

Enterococcus spp.E. faecalisATCC 51229 (VRE)0.5[53]
E. faeciumATCC 700221 (VRE)
Staphylococcus spp.S. aureusVRSA {15}/MRSA {15}0.125–0.5
MSSA {4}/VISA {3}0.125–0.25
S. epidermidisNRS 1010.5

M. tuberculosisH37Rv100[59]
XDR and MDR clinical isolates50

{ }: number of isolates; MIC90; μM; VRSA: vancomycin-resistant Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; MSSA: methicillin-susceptible Staphylococcus aureus; VISA: vancomycin-intermediate Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus spp.; ATCC: American Type Culture Collection.